Advancing High Quality Treatment for Opioid Use Disorders in Medicare Act
Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.
Advancing High Quality Treatment for Opioid Use Disorders in Medicare Act
(Sec. 2) This bill requires the Centers for Medicare & Medicaid Services (CMS) to carry out a demonstration program to: (1) increase access to opioid-use disorder treatment services for Medicare beneficiaries, (2) improve physical and mental health outcomes for such beneficiaries, and (3) reduce Medicare expenditures.
Opioid-use disorder care teams of practitioners may apply for participation in the demonstration project. The CMS must establish a performance-based incentive payment for participants.
(Sec. 3) The bill also requires prescriptions for controlled substances that are covered under the Medicare prescription drug benefit or Medicare Advantage prescription drug plans to be transmitted via electronic prescription programs. The CMS may waive such requirements under specified circumstances.
Received in the Senate and Read twice and referred to the Committee on Finance.
- Engrossed in House Formatted Text PDF Formatted XML
- Introduced in House Formatted Text PDF Formatted XML
- Referred in Senate Formatted Text PDF Formatted XML
- Reported in House Formatted Text PDF Formatted XML
Cite this page
U.S. Congress. (2026). H.R. 5605: Advancing High Quality Treatment for Opioid Use Disorders in Medicare Act. 115th Congress. Open America. https://openamerica.io/bill/115-HR-5605/
"H.R. 5605: Advancing High Quality Treatment for Opioid Use Disorders in Medicare Act." 115th Congress, 2026, Open America, https://openamerica.io/bill/115-HR-5605/.
H.R. 5605, 115th Cong. (2026), https://openamerica.io/bill/115-HR-5605/.
[H.R. 5605: Advancing High Quality Treatment for Opioid Use Disorders in Medicare Act](https://openamerica.io/bill/115-HR-5605/)